Table 2.
Participants criteria (N = 50)
| Variables at the AHSCT time | Outcome variables | ||
|---|---|---|---|
| Features | Median (Rang) / Frequency (%) | Features | Median (Rang) / Frequency (%) |
| Age (year) | 40.5 (18–70) | Hemoglobin (g/dl) | 12.3 (8.8–16.2) |
| Gender | WBC (×10 3 /µl) | 5.03 (2.8–10.2) | |
| Male | 25 (50%) | PLT (×10 3 /µl) | 178 (133–295) |
| Female | 25 (50%) | ESR (mm/hours) | 13.5 (2–82) |
| Diagnosis | LDH (U/L) | 287 (148–450) | |
| Multiple myeloma | 24 (48%) | Ca (mg/dl) | 9.3 (7.8–13) |
| Hodgkin lymphoma | 15 (30%) | Cr (mg/dl) | 1.03 (0.6-2.0) |
| Non-Hodgkin lymphoma | 11(22%) | ALP (IU/L) | 102 (51–373) |
| BMI after transplantation | 27.1 (14.8–42.1) | Urea (mg/dl) | 18 (11–23) |
| Relapse | 9 (18%) | ||
| Mobilization day number | 6 (5–9) |
Positive lytic lesion (In MM patients) |
2 (8%) |
| Total dose of infused G-CSF for mobilization (µg) | 3750 (1500–7200) | Positive M protein spike | 4 (16%) |
| WBC count at start day of mobilization (×10 3 /µl) | 6.05 (2.4–22.1) | Positive radiologic signs in lymphoma patients | 6 (23%) |
| Last injection of G-CSF to apheresis (hour) | 6 (1–22) | ||
| Neutrophil count on apheresis day (×10 3 /µl) | 35.13 (10.7–94.5) | ||
| Apheresis duration (min) | 377.5 (270–520) | ||
| Total processed blood in apheresis (Littr) | 17.97 (10.4–25.5) | ||
| WBC count in apheresis product (×10 8 /kg) | 10.9 (4.2–26.2) | ||
| MNC count in apheresis product (×10 8 /kg) | 6.20 (3.3–17.5) | ||
| CD34 + cell count/kg (×10 6 /kg) | 3.5 (1-15.4) | ||
| CD34 + in PAPBS (/µl) | 35 (4.1–116) | ||
| Platelet engraftment day | 11 (9–19) | ||
| Platelet count at engraftment day (×10 3 /µl) | 28 (20–110) | ||
BMI: Body mass index, WBC: White blood cell, MNC: Mono nuclear cell, PAPBS: Pre-apheresis peripheral blood sample, ESR: Erythrocyte sedimentation rate, LDH: Lactate dehydrogenase, Ca: Calcium, Cr: Creatinine, ALP: Alkaline phosphatase